US Patent 11241512 Stabilized radio-labeled anti-CD45 immunoglobulin compositions
Patent 11241512 was granted and assigned to actinium pharmaceuticals, inc. on February, 2022 by the United States Patent and Trademark Office.
All edits
Edits on 13 Dec, 2023
Golden AI
Edits made to:
Article (+411 characters)
Article
Patent abstract
Compositions and methods are described for stabilizing a radio-iodinated monoclonal IgG antibody for up to 17 days against radiolytic decomposition. The stabilized radiolabeled murine antibody binding the CD45 antigen expressed on various forms of lymphomas is useful as a radio-therapeutic and diagnostic agent in the treatment of human malignancies of hematopoietic origin, including lymphomas.
Edits on 15 Oct, 2023
Golden AI
Edits made to:
Infobox (+2 properties)
Infobox
Patent Inventor Names
Kaushik Dave0
Shubh Sharma0
Edits on 23 May, 2023
Golden AI
Edits made to:
Infobox (-1 properties)
Infobox
Official Website
Edits on 25 Mar, 2023
Golden AI
Infobox
Edits on 26 Sep, 2022
Golden AI
Infobox
Is a
Patent Applicant
0
Current Assignee
0
Patent Jurisdiction
Patent Number
112415120
Date of Patent
February 8, 2022
0Patent Application Number
164566140
Date Filed
June 28, 2019
0Official Website
Patent Primary Examiner
Edits on 17 Jun, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Website URL
Edits on 9 Feb, 2022
Golden AI
Edits made to:
Infobox (+10 properties)
US Patent 11241512 Stabilized radio-labeled anti-CD45 immunoglobulin compositions
Infobox
Is a
Patent applicant
Current assignee
Patent jurisdiction
Patent number
11241512
Date of patent
February 8, 2022
Patent application number
16456614
Date Filed
June 28, 2019
Patent primary examiner
Find more entities like US Patent 11241512 Stabilized radio-labeled anti-CD45 immunoglobulin compositions
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
